SCHEMBL2958196

SCHEMBL2958196

CSc1cccc(Nc2c(C(N)=O)sc3c2ccc(=O)n3-c2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
MAPT P10636 5/20 0.40
POLB P06746 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.39
TERT O14746 1/20 0.38
HPGD P15428 4/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
ALDH1A1 P00352 3/20 0.37
PPARG P37231 1/20 0.36
NCOA1 Q15788 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960252 0.88 UBE2M (0.36) MAPTMAPK1KDM4ETSHRALDH1A1
SCHEMBL2956387 0.87 MAPT (0.43) MEN1KMT2AMAPTPOLBHSD17B10
SCHEMBL2955772 0.87 CYP3A4 (0.39) MEN1KMT2AMAPTPOLBTP53
SCHEMBL2958575 0.87 CDK4 (0.38) MEN1KMT2AMAPTHSD17B10SMN1; SMN2
SCHEMBL2956783 0.85 PDE4B (0.42) MAPTPOLBTP53SMN1; SMN2KDM4E
SCHEMBL2952784 0.85 NPC1 (0.41) MEN1KMT2AMAPTTP53KDM4E
SCHEMBL2955616 0.85 TDO2 (0.41) MAPTPOLBTP53SMN1; SMN2ALDH1A1
SCHEMBL2950080 0.83 CSF1R (0.42) HSD17B10SMN1; SMN2MAPK1ALDH1A1
SCHEMBL2960203 0.83 MAPT (0.45) MEN1KMT2AMAPTPOLBTP53
SCHEMBL2952663 0.82 EGFR (0.38) MEN1KMT2AMAPTPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK MEN1 4273/4885KMT2A 1316/4885MAPT 4305/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 MEN1 3906/4885KMT2A 1383/4885MAPT 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.